Propanc Biopharma (PPCB) Profit After Tax (2010 - 2025)
Propanc Biopharma (PPCB) posted quarterly Profit After Tax of -$4.0 million for Q4 2025, down 837.16% year-over-year from $546897.2 in Q4 2024, and up 16.67% quarter-over-quarter from -$4.8 million in Q3 2025.
Propanc Biopharma (PPCB) Profit After Tax (2010 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Profit After Tax for 16 consecutive years, with -$4.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Profit After Tax fell 837.16% year-over-year to -$4.0 million; the TTM figure through Dec 2025 stood at -$12.9 million (down 280.57% YoY), while the FY2025 annual figure was -$58.9 million, down 2787.7% from the prior year.
- Profit After Tax improved to -$4.0 million in Q4 2025 per PPCB's latest filing, from -$4.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at $2.3 million in Q2 2023 and bottomed at -$4.8 million in Q3 2025.
- Historically, Profit After Tax has averaged -$1.2 million across 5 years, with a median of -$555542.0 in 2023.
- On a YoY basis, Profit After Tax climbed as much as 187.32% in 2023 and fell as far as 1296.1% in 2023.
- Propanc Biopharma's Profit After Tax stood at -$799977.0 in 2021, then jumped by 39.32% to -$485418.0 in 2022, then decreased by 20.39% to -$584384.0 in 2023, then gained by 26.39% to -$430183.0 in 2024, then sank by 837.16% to -$4.0 million in 2025.
- Business Quant data shows PPCB's Profit After Tax at -$4.0 million in Q4 2025, -$4.8 million in Q3 2025, and -$4.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | -4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.03 Mn |
| Sep 30, 2025 | -4.84 Mn |
| Jun 30, 2025 | -4.02 Mn |
| Mar 31, 2025 | -27,311.00 |
| Dec 31, 2024 | -430,183.00 |
| Sep 30, 2024 | -354,310.00 |
| Jun 30, 2024 | -2.08 Mn |
| Mar 31, 2024 | -526,700.00 |
| Dec 31, 2023 | -584,384.00 |
| Sep 30, 2023 | -350,866.00 |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | -769,195.00 |
| Dec 31, 2022 | -485,418.00 |
| Sep 30, 2022 | -617,295.00 |
| Jun 30, 2022 | -2.66 Mn |
| Mar 31, 2022 | -55,096.00 |
| Dec 31, 2021 | -799,977.00 |
| Sep 30, 2021 | -490,658.00 |
| Jun 30, 2021 | -2.39 Mn |
| Mar 31, 2021 | 29,723.00 |